Editorial: Next generation γδ T cell-based tumor immunotherapy

Andy Hee-Meng Tan; Alice Man Sze Cheung; Dieter Kabelitz

doi:10.3389/fimmu.2022.1041362

Editorial: Next generation γδ T cell-based tumor immunotherapy

Front Immunol. 2022 Sep 30:13:1041362. doi: 10.3389/fimmu.2022.1041362. eCollection 2022.

Authors

Andy Hee-Meng Tan¹, Alice Man Sze Cheung^{2

3}, Dieter Kabelitz⁴

Affiliations

¹ Immune Cell Manufacturing, Bioprocessing Technology Institute Agency for Science, Technology and Research (ASTAR), Singapore, Singapore.
² Department of Hematology, Singapore General Hospital, Singapore, Singapore.
³ SingHealth Duke-National University of Singapore (NUS) Medicine Academic Clinical Programme, Singapore, Singapore.
⁴ Institute of Immunology, University of Kiel, Kiel, Germany.

No abstract available

Keywords: butyrophilins; chimeric antigen receptor-engineered gamma delta T cells; cost-effective manufacturing of gamma delta t cell therapies; cytokine programming; gamma delta (γδ) T cells; gamma delta TCR repertoire; phosphoantigens; tumor immunotherapy.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immunotherapy*
Neoplasms* / therapy
Receptors, Antigen, T-Cell, gamma-delta

Substances

Receptors, Antigen, T-Cell, gamma-delta